Biogen, Scribe to develop additional gene therapy disease target
vchal/iStock via Getty Images         

Biogen (NASDAQ:BIIB) has exercised an option to develop another gene therapy disease target as part of a collaboration with Scribe Therapeutics.
The disease target was not disclosed.
When the collaboration began in 2020, the companies agreed to develop CRISPR-based therapies addressing an underlying genetic cause of amyotrophic lateral sclerosis.
Check out why Seeking Alpha contributor E. Roudasev says that Biogen (BIIB) is a buy.